Skip to product information
Crizotinib - Lucicriz
KSh76,000.00
|
What it treats: |
|
|
Lung cancer |
Crizotinib is a targeted cancer therapy primarily used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations, such as ALK (anaplastic lymphoma kinase) or ROS1 rearrangements. It works as a tyrosine kinase inhibitor, blocking the activity of these mutated proteins to slow or stop cancer cell growth. It’s typically prescribed for patients with advanced or metastatic NSCLC confirmed to have ALK or ROS1 alterations through genetic testing. |
|
Lymphoma cancer |
Crizotinib may be used in some cases for other cancers, like ALK-positive anaplastic large cell lymphoma (ALCL) or inflammatory myofibroblastic tumors (IMT) |
|
|
|